1
ALL1
Procaps GroupYear
1
ALL1
2023DEALS // DEV.
1
ALL1
DealsCountry
1
ALL1
LUXEMBOURG1
ALL1
BDR PharmaceuticalsTherapeutic Area
1
ALL1
OncologyStudy Phase
1
ALL1
UndisclosedDeal Type
1
ALL1
AgreementProduct Type
1
ALL1
UndisclosedDosage Form
1
ALL1
IntravenousLead Product
1
ALL1
UndisclosedTarget
1
ALL1
Tyrosine kinaseLead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : BDR Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Procaps Group Announces the Expansion of its Oncology Portfolio
Details : Under the agreement, Procaps will be responsible for registration, branding, marketing and commercialization of 27 oncology molecules for Latin America, including 20 TKIs (Tirosyne Kinase Inhibitors).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : BDR Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement